Aaron Wealth Advisors LLC Takes Position in Elanco Animal Health Incorporated $ELAN

Aaron Wealth Advisors LLC purchased a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 31,199 shares of the company’s stock, valued at approximately $628,000.

Several other large investors have also recently added to or reduced their stakes in ELAN. First Horizon Advisors Inc. lifted its position in Elanco Animal Health by 184.3% in the second quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company’s stock valued at $53,000 after purchasing an additional 2,414 shares during the period. Caitong International Asset Management Co. Ltd raised its stake in shares of Elanco Animal Health by 261.6% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 4,039 shares of the company’s stock worth $58,000 after buying an additional 2,922 shares in the last quarter. Geneos Wealth Management Inc. lifted its holdings in shares of Elanco Animal Health by 53.7% in the 2nd quarter. Geneos Wealth Management Inc. now owns 5,954 shares of the company’s stock valued at $85,000 after buying an additional 2,080 shares during the period. EverSource Wealth Advisors LLC boosted its stake in shares of Elanco Animal Health by 26.4% in the second quarter. EverSource Wealth Advisors LLC now owns 6,379 shares of the company’s stock valued at $91,000 after buying an additional 1,332 shares in the last quarter. Finally, Parallel Advisors LLC boosted its stake in shares of Elanco Animal Health by 66.6% in the second quarter. Parallel Advisors LLC now owns 6,432 shares of the company’s stock valued at $92,000 after buying an additional 2,572 shares in the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Barclays assumed coverage on Elanco Animal Health in a research report on Tuesday, December 9th. They issued an “overweight” rating and a $30.00 price objective for the company. UBS Group upped their price target on shares of Elanco Animal Health from $25.00 to $27.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Zacks Research cut shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 6th. Wall Street Zen raised shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 15th. Finally, KeyCorp restated an “overweight” rating on shares of Elanco Animal Health in a research report on Wednesday, December 10th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Elanco Animal Health presently has an average rating of “Moderate Buy” and an average target price of $23.78.

Elanco Animal Health Stock Performance

Shares of ELAN opened at $22.12 on Friday. Elanco Animal Health Incorporated has a 12-month low of $8.02 and a 12-month high of $23.70. The stock has a market cap of $10.99 billion, a P/E ratio of 368.73, a PEG ratio of 3.38 and a beta of 1.86. The company has a current ratio of 2.40, a quick ratio of 1.23 and a debt-to-equity ratio of 0.59. The company has a 50-day moving average of $21.87 and a two-hundred day moving average of $18.28.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.13 by $0.06. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The business had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same period in the prior year, the business earned $0.13 earnings per share. The company’s quarterly revenue was up 10.4% on a year-over-year basis. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. As a group, research analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Rajeev A. Modi acquired 4,500 shares of the firm’s stock in a transaction that occurred on Thursday, December 11th. The shares were acquired at an average price of $21.33 per share, with a total value of $95,985.00. Following the completion of the purchase, the insider directly owned 123,082 shares in the company, valued at approximately $2,625,339.06. The trade was a 3.79% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Robert M. Vanhimbergen acquired 6,950 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The shares were bought at an average price of $21.64 per share, with a total value of $150,398.00. Following the transaction, the chief financial officer owned 124,233 shares in the company, valued at $2,688,402.12. This represents a 5.93% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 43,450 shares of company stock worth $937,883 in the last 90 days. Corporate insiders own 0.89% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.